Online inquiry

IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9407MR)

This product GTTS-WQ9407MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PTPRC gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001267798.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5788
UniProt ID P08575
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ9407MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ113MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ5463MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ6387MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ5537MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ3192MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ2088MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ5050MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ6958MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW